Physician

Janet Luyu Wang

According to 2025 Medicare claims, Janet Wang (NPI: 1760629158) practices hematology/oncology in the Santa Cruz-Watsonville, CA market, with the plurality of this provider's patient population coming from Santa Cruz, CA. This provider's primary affiliated billing organization is SUTTER BAY MEDICAL FOUNDATION (NPI: 1013950807; TIN: 941156581) and primary practice location at 95065-1702. Wang is affiliated with the Sutter Medicare Direct (ACO ID: A5279), participating under the MSSP model.

Wang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,038 traditional Medicare patients, billed 304,624 HCPCS/CPT codes, and received $5,350,728 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,325 prescription claims across 236 beneficiaries totaling $2,672,916 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 93 claims. Open Payments data shows 12 records totaling $287. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,374,730 to $5,350,728. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $643,883 to $2,672,916. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $2,400 to $5,542.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	565	61,101	$1,374,730
2016	581	113,985	$1,723,398
2017	646	161,661	$2,395,797
2018	757	191,670	$2,828,071
2019	792	190,134	$3,239,705
2020	755	192,708	$3,697,772
2021	755	165,003	$2,980,953
2022	852	181,296	$3,183,306
2023	915	231,428	$4,304,181
2024	1,038	304,624	$5,350,728

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	109	539	$643,883
2016	140	662	$448,516
2017	184	975	$647,040
2018	220	1,223	$1,643,294
2019	207	1,267	$2,186,041
2020	213	1,150	$2,198,389
2021	197	904	$1,736,723
2022	191	881	$1,567,622
2023	202	1,092	$2,211,243
2024	236	1,325	$2,672,916

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	34	$20,502
2016	12	99	$39,395
2017	25	124	$32,183
2018	29	76	$14,827
2019	N/R	43	$7,061
2020	N/R	122	$12,028
2021	N/R	96	$6,991
2022	12	137	$7,355
2023	N/R	116	$25,780
2024	N/R	93	$2,620

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	127	335	$152
96413	Administration of chemotherapy into vein, 1 hour or less	158	585	$119
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	314	701	$104
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	208	280	$70
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	255	607	$56

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	53	1,518	$739,855
Ibrance	Palbociclib	23	646	$366,592
Jakafi	Ruxolitinib Phosphate	17	510	$296,846
Lynparza	Olaparib	17	510	$253,354
Revlimid	Lenalidomide	11	308	$235,466

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	46	$1,867
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	28	$527
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	19	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	12	$287	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Janet Luyu Wang?

Tedicare shows public-source Medicare data for Janet Luyu Wang (NPI 1760629158), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Janet Luyu Wang have ACO affiliation data?

Janet Luyu Wang is shown with ACO affiliation data for Sutter Medicare Direct (MSSP, ACO ID A5279).

What billing organization is linked to Janet Luyu Wang?

Janet Luyu Wang is linked to SUTTER BAY MEDICAL FOUNDATION (billing NPI 1013950807) in the available physician profile data.

Does Janet Luyu Wang have Open Payments data?

Janet Luyu Wang has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.